Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network

Many VEXAS patients report a partial benefit from cDMARDs, while a smaller yet not negligible number of patients exhibit a CR; cDMARDs remain a viable option for this disorder, especially when the initial GC dosage is low and the need for a steroid-sparing effect is not immediately urgent.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2025-03-07
DOI
https://doi.org/10.3389/fphar.2025.1539756
Citations
6
Primary Topic
Otitis Media and Relapsing Polychondritis
Type
article
Field-Weighted Citation Impact
10.01

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network

Guillermo Ruiz‐Irastorza, Monica Bocchia, Gaafar Ragab, Andrea Hinojosa‐Azaola et al.
6 citations
Frontiers in Pharmacology
Otitis Media and Relapsing Polychondritis
10.01
article

Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network

Guillermo Ruiz‐Irastorza, Monica Bocchia, Gaafar Ragab, Andrea Hinojosa‐Azaola, Henrique Ayres Mayrink Giardini, Florenzo Iannone, Guillermo Arturo Guaracha-Basáñez, Bruno Frediani, Amato de Paulis, Giuseppe Lopalco, Carlomaurizio Montecucco, Franco Franceschini, Valeria Caggiano, Antonio Vitale, Paola Triggianese, Ombretta Viapiana, Lorenzo Dagna, Abdurrahman Tufan, Matteo Piga, Chiara Baggio, Paolo Sfriso, Francesca Crisafulli, Alessandro Tomelleri, Alberto Cauli, Alberto Balistreri, Sara Bindoli, Corrado Campochiaro, Adriana Soto-Peleteiro, Karina Jahnz‐Różyk, José Hernández‐Rodríguez, Ewa Więsik–Szewczyk, Francesca Leone, Luca Cantarini, Francesco La Torre, Perla Ayumi Kawakami‐Campos, Carmelo Gurnari, İbrahim Vasi, Verónica Gómez‐Caverzaschi, Edoardo Conticini, Eduardo Martín‐Nares, Alejandra de‐la‐Torre, Andrés González García, Riccardo Bixio, Alicia Callisto, Francesco Gavioli, Jiram Torres‐Ruiz, Sara M. Monti, Mark Beecher, Ilaria Mormile, Rosetta Vitetta, Pravin Hissaria, Micol Frassi, Jurgen Sota, Olga Araújo, Rafael Alves Cordeiro, Ezgi Deniz Batu, Claudia Fabiani, Maria Antonietta D’Agostino, Jessica Sbalchiero, Mercedes Peña-Rodríguez
article en
6 citations

Abstract

Many VEXAS patients report a partial benefit from cDMARDs, while a smaller yet not negligible number of patients exhibit a CR; cDMARDs remain a viable option for this disorder, especially when the initial GC dosage is low and the need for a steroid-sparing effect is not immediately urgent.

Frontiers in PharmacologyVol. 16
University of Siena (IT), Università Cattolica del Sacro Cuore (IT), South Australia Pathology (AU), University of Rome Tor Vergata (IT), Cleveland Clinic (US), Royal Adelaide Hospital (AU), University of Padua (IT), Cairo University (EG), Vita-Salute San Raffaele University (IT), University of the Basque Country (ES), University of Cagliari (IT), University of Pavia (IT), BioCruces Health research Institute (ES), Azienda Ospedaliera Universitaria Integrata Verona (IT), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX), CTO Andrea Alesini (IT), Instituto Ramón y Cajal de Investigación Sanitaria (ES), IRCCS Ospedale San Raffaele (IT), Azienda Ospedaliera Universitaria Senese (IT), Policlinico Tor Vergata (IT), Central Clinical Hospital (PL), Ospedale Pediatrico Giovanni XXIII (IT), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Hospital Universitario Ramón y Cajal (ES), University of Bari Aldo Moro (IT), Hacettepe University (TR), University of Naples Federico II (IT), Universitat de Barcelona (ES), University of Brescia (IT), Universidad del Rosario (CO), Gazi University (TR)
Università degli Studi di Siena
Good health and well-being
Openalex Percentile: Top 2%
Otitis Media and Relapsing Polychondritis
10.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.